+ Watch AGIO
on My Watchlist
Remember the great biopharma IPO boom of mid-2013? Yeah, it's over. Turns out we haven't entered a new age of limitless valuations a la 2001. It was just some momos making quick money, and some followers getting taken to the cleaners. Same old story.Agios still hasn't fallen all the way back down to the true IPO price of 18, although it's way below the price at the close of the first day of trading. My first red thumb came when the market cap passed the one billion mark and it paid off handsomely. I can't say I'm enormously excited about the stock at a 700M cap but Portefeuille has decided this is where we're going to start our position, so I'm greenthumbing to back up a 100 share buy at 22.89 for the zzporte collaboration. Hopefully good things will come of the Celgene partnership once the mutant isocitrate dehydrogenase inhibitors are in clinical trials.
rc - celg backed
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions